Portal de Periódicos da CAPES

Potential of Stem/Progenitor Cells in Treating Stroke: The Missing Steps in Translating Cell Therapy from Laboratory to Clinic

2008; Future Medicine; Volume: 3; Issue: 3 Linguagem: Inglês

10.2217/17460751.3.3.249

1746-076X

Cesar V. Borlongan, Michael Chopp, Gary K. Steinberg, Tonya Bliss, Yi Li, Mei Lü, David C. Hess, Douglas Kondziolka,

Pluripotent Stem Cells Research

Regenerative MedicineVol. 3, No. 3 EditorialFree AccessPotential of stem/progenitor cells in treating stroke: the missing steps in translating cell therapy from laboratory to clinicCesar V Borlongan, Michael Chopp, Gary K Steinberg, Tonya M Bliss, Yi Li, Mei Lu, David C Hess & Douglas KondziolkaCesar V Borlongan† Author for correspondenceMedical College of Georgia and Augusta VA Medical Center, Department of Neurology, 1120 15th Street Augusta, GA 30904, USA , Michael ChoppHenry Ford Hospital, Department of Neurology, 2799 West Grand Blvd., Detroit, MI 48202, USA, Gary K SteinbergStanford University School of Medicine, Department of Neurosurgery, R281, 300 Pasteur Drive, Stanford, CA, 94305, USA, Tonya M BlissStanford University School of Medicine, Department of Neurosurgery, R281, 300 Pasteur Drive, Stanford, CA, 94305, USA, Yi LiHenry Ford Hospital, Department of Neurology, 2799 West Grand Blvd., Detroit, MI 48202, USA, Mei LuHenry Ford Hospital, Department of Neurology, 2799 West Grand Blvd., Detroit, MI 48202, USA, David C HessMedical College of Georgia and Augusta VA Medical Center, Department of Neurology, 1120 15th Street Augusta, GA 30904, USA & Douglas KondziolkaUniversity of Pittsburgh, Department of Neurological Surgery, Suite B-400, UPMC, 200 Lothrop Street Pittsburgh, PA 15213, USAPublished Online:7 May 2008https://doi.org/10.2217/17460751.3.3.249AboutSectionsPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInReddit Accumulating laboratory evidence demonstrates the potential of transplanting stem/progenitor cells for treating CNS disorders. The realization of neuroprotection or neurorestoration in the CNS challenges the central dogma that the brain is not capable of regeneration during aging or after injury. However, despite the encouraging results that lend support to CNS regeneration, critical gating items remain that limit the translation of the laboratory findings into meaningful clinical applications of cell therapy for stroke. Foremost among the several important preclinical factors that will require additional laboratory tests and validations is the establishment of a consortium of stem cell and stroke experts who will be able to independently analyze the efficacy and safety of cell therapy in stroke.The continued failure in drug clinical trials for treatment of acute stroke has been attributed to poor experimental designs of the drug development programs that do not adhere to the Stroke Therapy Academic Industry Round Table (STAIR) guidelines. However, the recent NXY-059 (Stroke-Acute Ischemic NXY Treatment [SAINT] II) trial still failed to achieve the expected efficacy despite including many of the STAIR criteria. Accordingly, there is an urgent call to revisit the stroke drug discovery pathway [1]. There is a clear and present need to develop a consortium approach including academia, government (US FDA/NIH) and pharmaceutical industry in drug-development programs. Equally important is recognizing the need for a translational medicine approach, in particular characterizing the drug candidate nature–target interaction, as well as determining the mechanisms underlying the phenotypic outcomes.To this end, responding to the STAIR call, our group (Borlongan, Chopp, Steinberg, Hess and Kondziolka), together with other stroke and cell-based therapy experts, and FDA and NIH representatives, played a key role in the first Stem cell Therapeutics as an Emerging Paradigm in Stroke (STEPS) Consortium meeting (October, 2007) whose main objective was to define several key areas that are deemed relevant to the development of cell-based, biologic and pharmacological restorative therapies (hereafter referred to as restorative therapies) for the treatment of stroke. Our guiding principle was to advocate science as the catalyst for designing preclinical studies so that we can most effectively and accurately translate this research to clinical practice. This preclinical STEPS workshop recommended the following translational criteria for designing laboratory studies on cell therapy for stroke:• The use of appropriate species and clinically relevant type of stroke models• The standardization of outcome measures and treatment protocols• The need for imaging of cell tracking and host response• The requirement for safety indices• A call for demonstrating mechanisms of action underlying restorative therapies in ischemic strokeTo the best of our knowledge, no studies on cell therapy for stroke incorporating all these STEPS preclinical workshop recommendations exist. Despite many rodent studies showing that cell transplantation can improve recovery from stroke, the variables responsible for the success of these therapies are largely unknown. Researchers have used different cell types, rodent strains, stroke models, transplant brain target locations and time points after stroke, and behavior tests to assess the transplant's efficacy (reviewed in [2–4]). Any or all of these parameters could be critical to the outcome of functional recovery. This lack of consistency in the field makes it very difficult to compare studies and truly ascertain the optimal conditions for cell transplant therapy following stroke. For example, is good functional recovery reported in one laboratory due to the cell type used or perhaps the behavior tests employed? The realization of a collaborative effort among multiple preclinical stroke laboratories evaluating the efficacy and safety of a particular stem/progenitor cell using the same testing paradigm until now remains a challenge. In order to address this significant gap in our knowledge, we have assembled a consortium of three established preclinical stroke laboratories, interfaced with a data coordination center and a clinical advisory board. We recognize that the establishment of such consortium between academics and industry, with close guidance from the NIH and FDA, is the first step towards realizing this laboratory-to-clinic translational goal, resonating the core principle of both STEPS and STAIR. Accordingly, our preclinical consortium incorporates all the STEPS criteria. The primary goal is to harness a collaboration across three established preclinical stroke laboratories (Borlongan, Chopp and Steinberg) that have extensive experience in conducting laboratory studies in multiple species (rat and mouse), strain, age and gender, characterizing a variety of focal stroke models using a standardized set of behavioral and histological outcome measures, and demonstrating mechanisms of action for testing the potential of restorative therapies in ischemic stroke.The fact that all three laboratories will carry out identical studies will help confirm the results for each parameter, which lends an unprecedented degree of veracity that is essential to a translational study. Investigation of the effect of age and gender on cell transplantation therapy is another novel aspect of our proposal as such parameters are generally overlooked in current rodent studies but are of critical clinical significance.Our individual laboratories have performed many of the studies proposed in the STEPS guidelines. Building on these extensive studies, we have elected to test the efficacy of two bone marrow stromal cell types (from SanBio, Inc., CA, USA, and Theradigm, Inc., MD, USA) administered at 1 month post-stroke. The 1-month time point was selected because it is clinically reasonable and desirable; neurological deficits are well defined, patients are stabilized and the extended therapeutic window permits nearly all ischemic patients to be enrolled. Two routes of cell administration, namely intracerebral (SanBio, Inc.) and intravenous (Theradigm, Inc.), will be employed. A dose-finding analysis will be performed for both cell types. Our proposed studies are therefore designed to develop treatment paradigms that can be readily translated to clinical stroke. We also seriously considered performing imaging experiments along the line of our recently published reports [5,6], which will be pursued in parallel studies. In addition, the establishment of a Data Coordination Center (Lu) and a Clinical Consortium (Hess and Kondziolka) as part of our investigative team should allow us to efficiently manage and evaluate the data, and assess the clinical relevance and applicability of our preclinical studies. Lastly, our industry partnerships with SanBio, Inc. and Theradigm, Inc. facilitates an ample supply of transplantable cells produced under good manufacturing practice, quality assurance and quality control regimen, which should expedite our translational goal of delivering a clinical grade product to the clinic. In summary, our preclinical STEPS consortium is desirous to deliver missing critical steps in the translational testing and validation of efficacy and safety of cell therapy in ischemic stroke, which, to date, has not been realized in the field of neurorestoration. Although these cell treatments have demonstrated therapeutic efficacy in individual laboratories [2–8], it is imperative for clinical translation that these cells be tested in multiple models of focal stroke, in two species, in both genders and in multiple laboratories.Financial & competing interests disclosure CV Borlongan and DC Hess are funded by NIH grants 1U01 NS055914 and 2R42 NS055606; CV Borlongan and D Kondziolka are Consultants to SanBio, Inc.; M Chopp is funded by NIH grants PO1 NS42345 and P50 NS23393; GK Steinberg is funded by NIH NINDS grants RO1 NS27292 and P01 NS37520, and is a stockholder in Cardium Therapeutics and has stock options in Stem Cells, Inc., and Neurofluidics. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.No writing assistance was utilized in the production of this manuscript.Bibliography1 Feuerstein GZ, Zaleska MM, Krams M et al.: Missing steps in the STAIR case: a translational medicine perspective on the development of NXY-059 for treatment of acute ischemic stroke. J. Cereb. Blood Flow Metab.28,217–219 (2008).Crossref, Medline, CAS, Google Scholar2 Chopp M, Li Y: Treatment of neural injury with marrow stromal cells. Lancet Neurol.1,92–100 (2002).Crossref, Medline, Google Scholar3 Bliss T, Guzman R, Daadi M, Steinberg GK: Cell transplantation therapy for stroke. Stroke38,817–826 (2007).Crossref, Medline, Google Scholar4 Borlongan CV, Fournier C, Stahl CE et al.: Gene therapy, cell transplantation and stroke. Front Biosci.11,1090–1101 (2006).Crossref, Medline, CAS, Google Scholar5 Chopp M, Zhang ZG, Jiang Q: Neurogenesis, angiogenesis, and MRI indices of functional recovery from stroke. Stroke38,827–831 (2007).Crossref, Medline, Google Scholar6 Guzman R, Uchida N, Bliss TM et al.: Long-term monitoring of transplanted human neural stem cells in developmental and pathological contexts with MRI. Proc. Natl Acad. Sci. USA104,10211–10216 (2007).Crossref, Medline, CAS, Google Scholar7 Hess DC, Borlongan CV: Stem cells and neurological diseases. Cell Prolif.41,94–114 (2008).Crossref, Medline, Google Scholar8 Kondziolka D, Wechsler L, Achim C: Neural transplantation for stroke. J. Clin. Neurosci.9,225–230 (2002).Crossref, Medline, Google ScholarFiguresReferencesRelatedDetailsCited ByIs Nrf2 Behind Endogenous Neuroprotection of the Hippocampal CA2-4,DG Region?22 December 2022 | Molecular Neurobiology, Vol. 59Mitochondrial activity of human umbilical cord mesenchymal stem cellsBrain Circulation, Vol. 7, No. 1Establishing a density-based method to separate proliferating and senescent cells from bone marrow stromal cells25 July 2020 | Aging, Vol. 12, No. 14Energy Metabolism Analysis of Three Different Mesenchymal Stem Cell Populations of Umbilical Cord Under Normal and Pathologic Conditions17 March 2020 | Stem Cell Reviews and Reports, Vol. 16, No. 3Mesenchymal stem cell therapy alleviates the neuroinflammation associated with acquired brain injury1 May 2020 | CNS Neuroscience & Therapeutics, Vol. 26, No. 6Harnessing the anti-inflammatory properties of stem cells for transplant therapy in hemorrhagic strokeBrain Hemorrhages, Vol. 1, No. 1Eyeballing stroke: Blood flow alterations in the eye and visual impairments following transient middle cerebral artery occlusion in adult rats25 February 2020 | Cell Transplantation, Vol. 29Stroke gets in your eyes: stroke-induced retinal ischemia and the potential of stem cell therapyNeural Regeneration Research, Vol. 15, No. 6Hypoxia conditioning enhances neuroprotective effects of aged human bone marrow mesenchymal stem cell-derived conditioned medium against cerebral ischemia in vitroBrain Research, Vol. 1725The brain and eye: Treating cerebral and retinal ischemia through mitochondrial transfer11 October 2019 | Experimental Biology and Medicine, Vol. 244, No. 16A Gutsy Move for Cell-Based Regenerative Medicine in Parkinson's Disease: Targeting the Gut Microbiome to Sequester Inflammation and Neurotoxicity17 July 2019 | Stem Cell Reviews and Reports, Vol. 15, No. 5Prophylactic treatment of hyperbaric oxygen treatment mitigates inflammatory response via mitochondria transfer11 April 2019 | CNS Neuroscience & Therapeutics, Vol. 25, No. 8Biodistribution of Glial Progenitors in a Three Dimensional-Printed Model of the Piglet Cerebral Ventricular SystemStem Cells and Development, Vol. 28, No. 8Hyperbaric oxygen therapy: A new look on treating stroke and traumatic brain injuryBrain Circulation, Vol. 5, No. 3Treating childhood traumatic brain injury with autologous stem cell therapy15 February 2018 | Expert Opinion on Biological Therapy, Vol. 18, No. 5Stroke TherapyMedia coverage and public awareness on bioethics perception of emerging biomedical therapies19 January 2017 | Chinese Neurosurgical Journal, Vol. 3, No. 1An update on stem cell therapy for neurological disorders: cell death pathways as therapeutic targets16 January 2017 | Chinese Neurosurgical Journal, Vol. 3, No. 1Translational considerations in injectable cell-based therapeutics for neurological applications: concepts, progress and challenges10 August 2017 | npj Regenerative Medicine, Vol. 2, No. 1Stem cell therapy for abrogating stroke-induced neuroinflammation and relevant secondary cell death mechanismsProgress in Neurobiology, Vol. 158Immunosuppression for in vivo research: state-of-the-art protocols and experimental approaches10 October 2016 | Cellular & Molecular Immunology, Vol. 14, No. 2Cell Therapy for Ischemic Stroke with Bone Marrow Stromal Cells7 January 2017Route, Cell Dose, and Timing7 January 2017Mobilization and Homing of Bone Marrow Stem Cells After Stroke15 December 2016Mesenchymal Stem Cells for Stroke Therapy15 December 2016Optogenetic modulation in stroke recoveryNeurosurgical Focus, Vol. 40, No. 5Current Opinion of Bone Marrow Stromal Cell Transplantation for Ischemic StrokeNeurologia medico-chirurgica, Vol. 56, No. 6Bone Marrow Endothelial Progenitor Cell Transplantation After Ischemic Stroke: An Investigation Into Its Possible Mechanism19 September 2015 | CNS Neuroscience & Therapeutics, Vol. 21, No. 11One, Two, Three Steps Toward Cell Therapy for StrokeStroke, Vol. 46, No. 2Stem Cell Therapy for Neonatal Hypoxic-Ischemic Encephalopathy12 August 2014 | Frontiers in Neurology, Vol. 5Behavioral and Histopathological Assessment of Adult Ischemic Rat Brains after Intracerebral Transplantation of NSI-566RSC Cell Lines10 March 2014 | PLoS ONE, Vol. 9, No. 3Stem Cell Transplantation for Neuroprotection in Stroke7 March 2013 | Brain Sciences, Vol. 3, No. 4An Update on Translating Stem Cell Therapy for Stroke from Bench to Bedside1 November 2013 | Journal of Clinical Medicine, Vol. 2, No. 4Vasculogenesis in Experimental Stroke After Human Cerebral Endothelial Cell TransplantationStroke, Vol. 44, No. 12Stem Cells in Cerebrovascular Diseases5 April 2013 | Journal of Molecular Neuroscience, Vol. 51, No. 2In Vivo Animal Stroke Models4 January 2013 | Translational Stroke Research, Vol. 4, No. 3Timing and cell dose determine therapeutic effects of bone marrow stromal cell transplantation in rat model of cerebral infarct21 June 2012 | Neuropathology, Vol. 33, No. 2Advances in the cell-based treatment of neonatal hypoxic–ischemic brain injuryMibel M Pabon & Cesar V Borlongan28 February 2013 | Future Neurology, Vol. 8, No. 2Different Sources of Stem Cells for Transplantation Therapy in Stroke27 November 2012Stem Cell Therapy for Cerebral Ischemia: From Basic Science to Clinical Applications18 January 2012 | Journal of Cerebral Blood Flow & Metabolism, Vol. 32, No. 7Intracerebral, but not intravenous, transplantation of bone marrow stromal cells enhances functional recovery in rat cerebral infarct: An optical imaging study18 October 2011 | Neuropathology, Vol. 32, No. 3Dietary Supplementations as Neuroprotective Therapies: Focus on NT-020 Diet Benefits in a Rat Model of Stroke15 June 2012 | International Journal of Molecular Sciences, Vol. 13, No. 6A Step-up Approach for Cell Therapy in Stroke: Translational Hurdles of Bone Marrow-Derived Stem Cells18 November 2011 | Translational Stroke Research, Vol. 3, No. 1Therapeutic Effects of Intra-Arterial Delivery of Bone Marrow Stromal Cells in Traumatic Brain Injury of Rats—In Vivo Cell Tracking Study by Near-Infrared Fluorescence ImagingNeurosurgery, Vol. 70, No. 2Advantages and challenges of alternative sources of adult-derived stem cells for brain repair in strokeBone marrow stem cell mobilization in stroke: a 'bonehead' may be good after all!26 May 2011 | Leukemia, Vol. 25, No. 11The great migration of bone marrow-derived stem cells toward the ischemic brain: Therapeutic implications for stroke and other neurological disordersProgress in Neurobiology, Vol. 95, No. 2Stem cell therapy in stroke: Designing clinical trialsNeurochemistry International, Vol. 59, No. 3Baby STEPS: A Giant Leap for Cell Therapy in Neonatal Brain InjuryPediatric Research, Vol. 70, No. 1Stem cells in stroke management21 December 2010 | Reviews in Clinical Gerontology, Vol. 21, No. 2Manual Vs Automated Delivery of Cells for Transplantation: Accuracy, Reproducibility, and Impact on ViabilityNeurosurgery, Vol. 67, No. 6Cellular transplantation for the nervous system: impact of time after preparation on cell viability and survivalJournal of Neurosurgery, Vol. 113, No. 3Optimizing the success of cell transplantation therapy for strokeNeurobiology of Disease, Vol. 37, No. 2Bone Marrow Stromal Cell Transplantation for Central Nervous System Disorders: Perspectives for Translational Research and Clinical ApplicationInjury-induced neural stem/progenitor cells in post-stroke human cerebral cortexEuropean Journal of Neuroscience, Vol. 31, No. 1Progress and perspective of bone marrow stromal cell transplantation for ischemic strokeNosotchu, Vol. 32, No. 6BIOLOGICAL RESTORATION OF CENTRAL NERVOUS SYSTEM ARCHITECTURE AND FUNCTIONNeurosurgery, Vol. 65, No. 5Severity of controlled cortical impact traumatic brain injury in rats and mice dictates degree of behavioral deficitsBrain Research, Vol. 1287STEPS toward the Right Direction1 July 2009 | Cell Transplantation, Vol. 18, No. 7Cell Therapy for StrokeStroke, Vol. 40, No. 3_suppl_1Experimental ModelsStroke, Vol. 40, No. 3_suppl_1Effects of progesterone administration on infarct volume and functional deficits following permanent focal cerebral ischemia in ratsBrain Research, Vol. 1257How should we bridge the missing steps in translational research for stroke therapy?-A critical reviewNosotchu, Vol. 30, No. 6 Vol. 3, No. 3 Follow us on social media for the latest updates Metrics History Published online 7 May 2008 Published in print May 2008 Information© Future Medicine LtdFinancial & competing interests disclosure CV Borlongan and DC Hess are funded by NIH grants 1U01 NS055914 and 2R42 NS055606; CV Borlongan and D Kondziolka are Consultants to SanBio, Inc.; M Chopp is funded by NIH grants PO1 NS42345 and P50 NS23393; GK Steinberg is funded by NIH NINDS grants RO1 NS27292 and P01 NS37520, and is a stockholder in Cardium Therapeutics and has stock options in Stem Cells, Inc., and Neurofluidics. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.No writing assistance was utilized in the production of this manuscript.PDF download